Nedaplatin in treating drug resistant nasopharyngeal carcinoma and non-small-cell lung cancer
- VernacularTitle:奈达铂治疗耐药性鼻咽癌和非小细胞肺癌
- Author:
Xiaohua HU
;
Weimin XIE
;
Zhihui LIU
;
Al ET
- Publication Type:Journal Article
- Keywords:
nasopharyngeal carcinoma;
non small cell lung cancer;
nedapltin;
drug resistance
- From:
China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the efficacy and safety of nedaplatin alone in treating drug resistant non small cell lung cancer and nasopharyngeal cancer.Methods:From June 2000 to March 2002,9 cases who were re treated non small cell lung cancer or nasopharyngeal cancer received nedaplatin chemotherapy. Nedaplatin was administered at a dose of 100mg/m 2 with 500 ml of saline by slow drip infusion for 120 minutes, at intervals of 3 4 weeks. Results:9 patients were studied, and 9 patients were evaluable. Among of them, 6 patients were nasopharyngeal carcinoma, a partial remission (PR) was observed in 2 patients, and a complete remission (CR) was observed in 1 patient. Partial response rate was 50% (3/6); 3 patients were non small cell lung cancer; partial response rate was 33.3%(1/3).The dose limiting toxicity of nedaplatin is thrombocytopenia and ieucocytopenia. Renal toxicity was not observed and gastrointestinal toxicity was mild.Conclusions:Nedaplatin is efficacious for DDP drug resistant nasopharyngeal carcinoma and non small cell lung cancer, and most patients whose tolerated the drug well. [
